To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
23 Current news of Medicago
rss |
You can refine your search further. Select from the filter options on the left to narrow down your results. |
Medicago to build $245M production facility in Quebec City
New complex will make vaccines and therapeutics using innovative plant technology
21-May-2015
Medicago announced that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago's Quebec City office and laboratories. The project is expected to generate more ...
Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology
18-Jan-2012
Medicago Inc. and Cellectis plant sciences, a subsidiary of Cellectis SA announced the signing of a research agreement under which Medicago and Cellectis will collaborate to improve therapeutic proteins expressed from tobacco leaves. "We look forward to working with Cellectis plant sciences to ...
Medicago announces research collaboration for the development of a non-influenza vaccine candidate
12-Apr-2011
Medicago Inc. announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.Under the terms of the research collaboration, Medicago will apply its transient expression system to develop a ...
Medicago announces an extension of its agreement with Genopole biopark
29-Nov-2010
Medicago Inc. announced an extension to its partnering agreement of July 2009 with Genopole®. Medicago and Genopole® will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health and biodefense. This laboratory is ...
Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs
27-Sep-2010
Medicago Inc. announced it has filed two international patent applications under the Patent Cooperation Treaty (PCT) that broadly cover new methods of preparing plant-derived recombinant proteins and VLPs. "The extraction and purification of recombinant proteins and complex structures such as ...
Medicago awarded $21 million from the U.S. Department of Defense
Medicago to develop a vaccine facility in Research Triangle Park, North Carolina
12-Aug-2010
Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., announced that it has been awarded a $21 Million grant from the Defense Advanced Research Projects Agency (DARPA), Broad Agency Announcement (BAA), Defense Sciences Research & Technology to demonstrate the scalable manufacturing of ...
Medicago signs MOU with NITT Partners for commercial development of influenza vaccines in Japan
19-Mar-2010
Medicago Inc. announced that it has signed a Memorandum of Understanding with Niigata TLO/NBRP/KUTLO-NITT ("NITT Partners") to discuss and negotiate an agreement to commercialize Medicago's pandemic and seasonal influenza VLP-based vaccines in Japan and other territories. For several years, NITT ...
Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
13-Oct-2009
Medicago Inc. announced that it has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center ("ECBC") Research & Technology Directorate. Medicago will work with ECBC to investigate the ...
Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
27-Aug-2009
Medicago Inc. announced that it has received clearance from Health Canada to commence a Phase I human clinical trial with its H5N1 Avian Influenza vaccine. Enrollment of volunteers is now underway. The Phase I placebo-controlled, double-blind, dose-escalating study will evaluate safety, ...
Medicago signs MOU with Ajanta Pharma for commercial development of influenza vaccines in India and other territories
25-Aug-2009
Medicago Inc. announced that it has signed a Memorandum of Understanding ("MOU") with Ajanta Pharma Limited to discuss and negotiate an agreement to commercialize Medicago's pandemic and seasonal influenza VLP-based vaccines in India and other territories. Under the terms of the MOU, the parties ...
